These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26573697)

  • 1. How to effectively manage the event of bleeding complications when using anticoagulants.
    Sartori MT; Prandoni P
    Expert Rev Hematol; 2016 Jan; 9(1):37-50. PubMed ID: 26573697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
    Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Direct oral anticoagulant associated bleeding].
    Godier A; Martin AC; Rosencher N; Susen S
    J Mal Vasc; 2016 Jul; 41(4):272-8. PubMed ID: 27297642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 6. [Management of hemorrhage in patients treated with direct oral anticoagulants].
    Grottke O; Lier H; Hofer S
    Anaesthesist; 2017 Sep; 66(9):679-689. PubMed ID: 28455651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding.
    Moia M; Squizzato A
    Intern Emerg Med; 2019 Nov; 14(8):1233-1239. PubMed ID: 31446606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants (DOAC) - Management of emergency situations.
    Lindhoff-Last E
    Hamostaseologie; 2017; 37(4):257-266. PubMed ID: 29582928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
    Le Roux P; Pollack CV; Milan M; Schaefer A
    J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
    Vavra KA; Lutz MF; Smythe MA
    Ann Pharmacother; 2010 Apr; 44(4):718-26. PubMed ID: 20233918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.
    Raimondi P; Hylek EM; Aronis KN
    Curr Pharm Des; 2017; 23(9):1406-1423. PubMed ID: 27917717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].
    Dempfle CE; Borggrefe M
    Internist (Berl); 2005 Sep; 46(9):1006-10, 1012-3. PubMed ID: 16082525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of bleeding complications in patients on anticoagulant therapy.
    Piran S; Schulman S
    Blood; 2019 Jan; 133(5):425-435. PubMed ID: 30559261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents.
    Di Fusco SA; Lucà F; Benvenuto M; Iorio A; Fiscella D; D'Ascenzo F; Madeo A; Colivicchi F; Di Lenarda A; Gulizia MM
    Int J Cardiol; 2018 Oct; 268():75-79. PubMed ID: 29843897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who, when, and how to reverse non-vitamin K oral anticoagulants.
    Aronis KN; Hylek EM
    J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing anticoagulant therapy.
    Ghanny S; Warkentin TE; Crowther MA
    Curr Drug Discov Technol; 2012 Jun; 9(2):143-9. PubMed ID: 22023256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine).
    Bekka E; Liakoni E
    Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38926082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.